Susquehanna International Group’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-62,200
| Closed | -$567K | – | 13691 |
|
|
2025
Q2 | $567K | Sell |
62,200
-24,700
| -28% | -$182K | ﹤0.01% | 8881 |
|
|
2025
Q1 | $691K | Buy |
86,900
+2,700
| +3% | +$19.8K | ﹤0.01% | 8178 |
|
|
2024
Q4 | $457K | Sell |
84,200
-77,500
| -48% | -$474K | ﹤0.01% | 8899 |
|
|
2024
Q3 | $1.17M | Buy |
161,700
+60,500
| +60% | +$554K | ﹤0.01% | 6432 |
|
|
2024
Q2 | $1.1M | Buy |
101,200
+39,900
| +65% | +$511K | ﹤0.01% | 6355 |
|
|
2024
Q1 | $1.15M | Sell |
61,300
-95,800
| -61% | -$2.21M | ﹤0.01% | 6556 |
|
|
2023
Q4 | $3.4M | Sell |
157,100
-179,600
| -53% | -$3.56M | ﹤0.01% | 4363 |
|
|
2023
Q3 | $6.93M | Buy |
336,700
+179,700
| +114% | +$5.19M | ﹤0.01% | 3034 |
|
|
2023
Q2 | $7.38M | Sell |
157,000
-36,300
| -19% | -$1.81M | ﹤0.01% | 2922 |
|
|
2023
Q1 | $8.11M | Buy |
193,300
+82,500
| +74% | +$3.55M | ﹤0.01% | 2754 |
|
|
2022
Q4 | $4.23M | Sell |
110,800
-39,300
| -26% | -$1.5M | ﹤0.01% | 3493 |
|
|
2022
Q3 | $5.88M | Buy |
150,100
+46,800
| +45% | +$1.81M | ﹤0.01% | 2911 |
|
|
2022
Q2 | $3.34M | Buy |
103,300
+50,200
| +95% | +$1.68M | ﹤0.01% | 3881 |
|
|
2022
Q1 | $1.76M | Sell |
53,100
-63,300
| -54% | -$2.38M | ﹤0.01% | 5768 |
|
|
2021
Q4 | $4.95M | Buy |
116,400
+39,300
| +51% | +$1.65M | ﹤0.01% | 3752 |
|
|
2021
Q3 | $3.42M | Sell |
77,100
-71,600
| -48% | -$3.28M | ﹤0.01% | 4682 |
|
|
2021
Q2 | $8.45M | Buy |
148,700
+50,900
| +52% | +$3.6M | ﹤0.01% | 3162 |
|
|
2021
Q1 | $7.32M | Sell |
97,800
-44,900
| -31% | -$3.68M | ﹤0.01% | 3275 |
|
|
2020
Q4 | $12.3M | Sell |
142,700
-52,900
| -27% | -$3.9M | ﹤0.01% | 2255 |
|
|
2020
Q3 | $12M | Buy |
195,600
+92,600
| +90% | +$4.69M | ﹤0.01% | 1982 |
|
|
2020
Q2 | $4.28M | Sell |
103,000
-7,300
| -7% | -$265K | ﹤0.01% | 3229 |
|
|
2020
Q1 | $3.17M | Sell |
110,300
-432,200
| -80% | -$25M | ﹤0.01% | 3202 |
|
|
2019
Q4 | $39.2M | Buy |
542,500
+327,900
| +153% | +$40.3M | 0.01% | 960 |
|
|
2019
Q3 | $30.1M | Buy |
214,600
+53,400
| +33% | +$8.93M | 0.01% | 1047 |
|
|
2019
Q2 | $29.5M | Sell |
161,200
-8,100
| -5% | -$1.38M | 0.01% | 1021 |
|
|
2019
Q1 | $26.9M | Sell |
169,300
-178,300
| -51% | -$25.8M | 0.01% | 989 |
|
|
2018
Q4 | $33.3M | Buy |
347,600
+193,500
| +126% | +$22.1M | 0.01% | 773 |
|
|
2018
Q3 | $21.8M | Buy |
154,100
+4,200
| +3% | +$648K | 0.01% | 1257 |
|
|
2018
Q2 | $23.5M | Sell |
149,900
-10,000
| -6% | -$1.57M | 0.01% | 1178 |
|
|
2018
Q1 | $25.8M | Sell |
159,900
-109,800
| -41% | -$18.6M | 0.01% | 1040 |
|
|
2017
Q4 | $44.4M | Sell |
269,700
-152,700
| -36% | -$14.8M | 0.02% | 751 |
|
|
2017
Q3 | $26.3M | Buy |
422,400
+310,400
| +277% | +$24.4M | 0.01% | 1037 |
|
|
2017
Q2 | $8.92M | Sell |
112,000
-221,900
| -66% | -$16M | ﹤0.01% | 1798 |
|
|
2017
Q1 | $23.7M | Buy |
333,900
+205,600
| +160% | +$12M | 0.01% | 959 |
|
|
2016
Q4 | $6.55M | Buy |
128,300
+30,900
| +32% | +$1.46M | ﹤0.01% | 2035 |
|
|
2016
Q3 | $4.49M | Buy |
97,400
+35,000
| +56% | +$1.42M | ﹤0.01% | 2376 |
|
|
2016
Q2 | $1.88M | Buy |
62,400
+9,300
| +18% | +$310K | ﹤0.01% | 3678 |
|
|
2016
Q1 | $1.7M | Buy |
53,100
+29,900
| +129% | +$1.05M | ﹤0.01% | 4079 |
|
|
2015
Q4 | $1.35M | Sell |
23,200
-6,000
| -21% | -$297K | ﹤0.01% | 4807 |
|
|
2015
Q3 | $1.24M | Buy |
29,200
+21,900
| +300% | +$1.35M | ﹤0.01% | 5250 |
|
|
2015
Q2 | $533K | Buy |
+7,300
| New | +$469K | ﹤0.01% | 7518 |
|
Other funds holding SAGE
IA
HNB
Susquehanna International Group's SAGE Position: Q3 2025 in Review
Susquehanna International Group sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 139,666 shares — an estimated $1.27M sold.
Susquehanna International Group first reported a position in SAGE in Q2 2015 and held it in 35 quarters. The position peaked at $43.6M in Q4 2017. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.
- Susquehanna International Group reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
- Susquehanna International Group sold 139,666 Sage Therapeutics shares in Q3 2025, an estimated $1.27M.
- Susquehanna International Group first reported a position in Sage Therapeutics in Q2 2015 and held it in 35 quarters.
- Susquehanna International Group's Sage Therapeutics position peaked at $43.6M in Q4 2017.
- 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.
Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.